6/14/2018
Kena Betancur/Getty Images

Merck's marketing application for the use of Gardasil 9, or human papillomavirus 9-valent vaccine, recombinant, in women and men ages 27 to 45 to prevent certain cancers and diseases caused by nine human papillomavirus types, was accepted by the FDA under priority review status with a PDUFA date of Oct. 6. The drug is approved for male and female patients ages 9 to 26.

Full Story:
Seeking Alpha

Related Summaries